Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff AM, Kaplan LM, Davies MJ, et al. New England Journal of Medicine 2026.
What it found
In adults with obesity and no diabetes, mean weight change was -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) vs -3.9% with placebo. Knee pain scores improved more than placebo in the 574 participants with knee osteoarthritis, and breathing interruptions during sleep fell more in the 243 with sleep apnoea. Gastrointestinal events were the most common side effects.
Limitations
Published online ahead of print in September 2026; volume and pages not yet assigned. Full safety data are in the paper, not the abstract. Funded and run by the developer.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.